

# Rosalba Miceli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7638142/publications.pdf>

Version: 2024-02-01

242  
papers

15,231  
citations

22548

61  
h-index

22488

117  
g-index

247  
all docs

247  
docs citations

247  
times ranked

17160  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. <i>Haematologica</i> , 2022, 107, 1153-1162.	1.7	15
2	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISGâ€TS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
3	Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 3274-3286.	0.7	5
4	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1723-1729.	0.5	10
5	Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 4376-4385.	0.7	12
6	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	0.6	5
7	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. <i>Tumori</i> , 2021, 107, 150-159.	0.6	8
8	Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. <i>Oncology</i> , 2021, 99, 84-95.	0.9	5
9	A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 3904-3916.	0.7	14
10	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 Years. <i>Annals of Surgical Oncology</i> , 2021, 28, 1700-1709.	0.7	38
11	Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4706-4717.	0.7	16
12	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 261-268.	1.3	8
13	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 7854-7863.	0.7	19
14	Severe COVID-19 in Hospitalized Carriers of Single CFTR Pathogenic Variants. <i>Journal of Personalized Medicine</i> , 2021, 11, 558.	1.1	16
15	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. <i>European Journal of Cancer</i> , 2021, 157, 291-300.	1.3	11
16	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	0.7	26
17	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020, 130, 857-865.	1.1	25
18	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. <i>Tumori</i> , 2020, 106, 39-46.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Reply to E. Hindi. Journal of Clinical Oncology, 2020, 38, 3238-3240.	0.8	3
20	Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. Frontiers in Oncology, 2020, 10, 1223.	1.3	2
21	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. Cancer, 2020, 126, 4917-4925.	2.0	21
22	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. European Journal of Cancer, 2020, 135, 62-65.	1.3	32
23	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Journal of Clinical Oncology, 2020, 38, 1591-1601.	0.8	50
24	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncology, The, 2020, 21, 947-956.	5.1	166
25	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Oncologist, 2020, 25, e460-e468.	1.9	29
26	Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1327-1336.	2.3	3
27	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. Dysphagia, 2019, 34, 52-62.	1.0	9
28	PO-160 Tumor and retropharyngeal nodal GTVs prognostic role in unresectable non-glandular sinonasal cancers. Radiotherapy and Oncology, 2019, 132, 85.	0.3	0
29	Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis. Annals of Surgical Oncology, 2019, 26, 3535-3541.	0.7	10
30	Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of ARO Head and Neck working group. Head and Neck, 2019, 41, 3684-3692.	0.9	17
31	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1268.	3.4	70
32	OC-0070 Radiation Therapy for Retroperitoneal Liposarcoma – A report from TARPSWG. Radiotherapy and Oncology, 2019, 133, S32.	0.3	0
33	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	0.8	293
34	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2019, 2, 699-707.	2.6	38
35	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. Pharmacogenomics Journal, 2019, 19, 465-472.	0.9	16
36	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. Journal of Pathology: Clinical Research, 2019, 5, 217-226.	1.3	29

#	ARTICLE	IF	CITATIONS
37	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	0.9	26
38	Outcome of ilio caval resection and reconstruction for retroperitoneal sarcoma. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2019, 7, 547-556.	0.9	22
39	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	3.2	80
40	Prevalence of Fatigue in Head and Neck Cancer Survivors. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2019, 128, 413-419.	0.6	30
41	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	3.2	42
42	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	2.0	71
43	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2019, 41, 1895-1902.	0.9	10
44	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 1047-1051.	3.3	27
45	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in <i>MGMT</i> methylated, <i>RAS</i> mutated metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3509-3509.	0.8	1
46	Extracellular matrix proteins as diagnostic markers of breast carcinoma. <i>Journal of Cellular Physiology</i> , 2018, 233, 6280-6290.	2.0	49
47	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1217-1221.	0.4	9
48	Prognostic models for RPS patients—Attempting to predict patient outcomes. <i>Journal of Surgical Oncology</i> , 2018, 117, 69-78.	0.8	16
49	Prognostic role of PIK3CA and TP53 in human papillomavirus—negative oropharyngeal cancers. <i>Tumori</i> , 2018, 104, 213-220.	0.6	4
50	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
51	Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 1203-1215.	0.4	2
52	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	2.1	142
53	Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy. <i>Annals of Oncology</i> , 2018, 29, viii311-viii312.	0.6	0
54	Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. <i>Head and Neck</i> , 2018, 40, 2648-2656.	0.9	7

#	ARTICLE	IF	CITATIONS
55	In Reply to Fakhry etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 102, 670-671.	0.4	1
56	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. European Journal of Cancer, 2018, 105, 19-27.	1.3	56
57	Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. BMC Cancer, 2018, 18, 899.	1.1	45
58	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist, 2018, 23, 1178-1187.	1.9	46
59	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European Journal of Cancer, 2018, 97, 7-15.	1.3	34
60	PV-0432: Impact of re-irradiation volume and dose on the survival of recurrent HN cancer: an AIRO study. Radiotherapy and Oncology, 2018, 127, S228-S229.	0.3	0
61	MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner. Journal of Hematology and Oncology, 2018, 11, 45.	6.9	23
62	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology, 2018, 95, 344-352.	0.9	11
63	A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.. Journal of Clinical Oncology, 2018, 36, 4502-4502.	0.8	7
64	Peritoneal Surface Oncology Group International (PSOGI) multicenter study on nomograms to predict overall survival in diffuse malignant peritoneal mesothelioma.. Journal of Clinical Oncology, 2018, 36, e15701-e15701.	0.8	0
65	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics Journal, 2017, 17, 331-336.	0.9	10
66	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 60-65.	0.6	4
67	Postâ€relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transâ€Atlantic RPS Working Group. Cancer, 2017, 123, 1971-1978.	2.0	104
68	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncology, 2017, 69, 33-37.	0.8	16
69	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clinical Genitourinary Cancer, 2017, 15, 509-512.e9.	0.9	1
70	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2017, 23, 1102-1109.	2.0	9
71	Soft tissue sarcoma nomograms and their incorporation into practice. Cancer, 2017, 123, 2802-2820.	2.0	105
72	Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leukemia Research, 2017, 62, 91-97.	0.4	16

#	ARTICLE	IF	CITATIONS
73	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017, 28, 2820-2826.	0.6	66
74	PD-034: Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 20.	0.3	0
75	Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2012-2020.	0.5	20
76	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	0.6	43
77	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 213-220.e5.	0.9	27
78	First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial. <i>Annals of Oncology</i> , 2017, 28, v629.	0.6	1
79	Predicting response to chemotherapy in gastric cancer patients randomized to docetaxel: A reevaluation of the ITACA-S trial. <i>Annals of Oncology</i> , 2017, 28, v41.	0.6	0
80	A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, vi68.	0.6	0
81	Predictive factors in GEP-NEN: The integrated role of Ki67, beta-catenin and morphology. <i>Annals of Oncology</i> , 2017, 28, v152-v153.	0.6	0
82	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9543-9543.	0.8	5
83	Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 59-59.	0.8	2
84	Sarcoma nomograms: a light over the darkness. <i>Oncoscience</i> , 2017, 4, 15-16.	0.9	6
85	Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 64-64.	0.8	0
86	Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4068-4068.	0.8	0
87	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). <i>Annals of Surgery</i> , 2016, 263, 1002-1009.	2.1	392
88	Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 64, 107-112.	1.3	60
89	External validation of a multi-institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016, 122, 1417-1424.	2.0	77
90	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	2.6	151

#	ARTICLE	IF	CITATIONS
91	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 671-680.	5.1	318
92	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. <i>Neuro-Oncology</i> , 2016, 18, 1451-1460.	0.6	108
93	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	0.9	12
94	Extracellular matrix proteins derived from the tumor microenvironment as circulating breast cancer diagnostic markers. <i>European Journal of Cancer</i> , 2016, 61, S42.	1.3	0
95	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3531-3540.	0.7	136
96	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 959-966.	0.4	48
97	Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting. <i>Annals of Oncology</i> , 2016, 27, vi342.	0.6	0
98	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 384-390.	1.3	7
99	Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 49-61.	0.6	108
100	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 1-4.	0.9	6
101	Osteopontin, E-cadherin, and $\beta$ -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	2.7	37
102	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11045-11045.	0.8	0
103	Individual patient data meta-analysis of the IMPACT of treatment site on the outcome of head and neck cancer patients treated within 6 randomized trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6022-6022.	0.8	0
104	Androgen receptor (AR) immunohistochemical (IHC) expression in muscle invasive (miUC) or metastatic urothelial carcinoma (mUC): Evaluating a potential target for treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16025-e16025.	0.8	0
105	2865 Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis. <i>European Journal of Cancer</i> , 2015, 51, S578.	1.3	3
106	Secondary electrospray ionization-mass spectrometry and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. <i>Journal of Breath Research</i> , 2015, 9, 031001.	1.5	25
107	3404 External validation of a nomogram predicting disease-free (DFS) and overall survival (OS) in patients (pts) with primary retroperitoneal sarcoma (pRPS). <i>European Journal of Cancer</i> , 2015, 51, S689-S690.	1.3	0
108	Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. <i>BMC Bioinformatics</i> , 2015, 16, 388.	1.2	16



#	ARTICLE	IF	CITATIONS
109	Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. <i>British Journal of Surgery</i> , 2015, 102, 1079-1087.	0.1	43
110	KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST. <i>American Journal of Surgical Pathology</i> , 2015, 39, 922-930.	2.1	63
111	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	2.1	101
112	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	1.2	22
113	416 Variant Alleles in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) or Methylenetetrahydrofolate Reductase (MTHFR) and risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients. <i>European Journal of Cancer</i> , 2015, 51, S83-S84.	1.3	0
114	Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. <i>European Journal of Cancer</i> , 2015, 51, 186-192.	1.3	133
115	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 1447-1454.	0.7	152
116	Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM+ Lung Cancer "Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 3636-3649.	0.4	83
117	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.3	28
118	Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4535-4535.	0.8	0
119	Translational research on molecular markers in gastric cancer patients treated with adjuvant therapy (Italian Intergroup Adjuvant Chemotherapy of Adenocarcinoma of the Stomach-ITACA-S Trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15016-e15016.	0.8	0
120	Postoperative morbidity and mortality in a large series of primary retroperitoneal sarcoma (RPS) treated at 8 tertiary centers: A study from the Transatlantic RPS Working Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10557-10557.	0.8	0
121	Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15527-e15527.	0.8	0
122	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	1.1	18
123	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. <i>Cancers</i> , 2014, 6, 1753-1768.	1.7	14
124	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	0.9	3
125	Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. <i>Journal of Neuro-Oncology</i> , 2014, 118, 305-312.	1.4	61
126	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. <i>Leukemia</i> , 2014, 28, 1885-1891.	3.3	83



#	ARTICLE	IF	CITATIONS
127	Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2479-2485.	0.8	103
128	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014, 25, 694-699.	0.6	33
129	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	0.9	24
130	Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib "Analysis of prognostic factors (EORTC-STBSG collaborative study). <i>European Journal of Surgical Oncology</i> , 2014, 40, 412-419.	0.5	125
131	Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) for males with HCG-expressing, chemorefractory germ cell tumors (GCT): Long-term efficacy and safety outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4561-4561.	0.8	2
132	Analysis of the contemporary use of high-dose chemotherapy (HDCT) in germ cell tumors (GCT) in Europe: Early findings of an ongoing EBMT-sponsored study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15536-e15536.	0.8	1
133	Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. <i>World Journal of Gastroenterology</i> , 2014, 20, 4516.	1.4	30
134	Predictive and prognostic significance of early positron emission tomography/computed tomography (PET/CT) in advanced transitional cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 341-341.	0.8	0
135	Nomograms to predict prognosis in pseudomyxoma peritonei: A Peritoneal Surface Oncology Group International (PSOGI) multicenter study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4033-4033.	0.8	0
136	Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine glioma in childhood.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10020-10020.	0.8	1
137	Abstract 2852: SNAI2 expression by cancer-associated fibroblasts is a negative prognostic factor in non-small cell lung cancer. , 2014, , .		0
138	Histological variants of medulloblastoma are the most powerful clinical prognostic indicators. <i>Pediatric Blood and Cancer</i> , 2013, 60, 210-216.	0.8	38
139	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013, 49, 413-419.	0.8	39
140	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. <i>Journal of Urology</i> , 2013, 190, 1919-1924.	0.2	36
141	Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. <i>Annals of Oncology</i> , 2013, 24, 2181-2189.	0.6	63
142	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013, 24, 2967-2971.	0.6	22
143	Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. <i>Journal of Clinical Oncology</i> , 2013, 31, 1649-1655.	0.8	268
144	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	2.0	162

#	ARTICLE	IF	CITATIONS
145	Cell Proliferation of the Primary Tumor Predicts Ipsilateral Axillary Node Disease in Elderly Breast Cancer Patients. <i>International Journal of Biological Markers</i> , 2013, 28, 24-31.	0.7	0
146	High pathologic response rate of hepatic colorectal cancer metastases (HCRM) following neoadjuvant bevacizumab (Bev)-based treatment (tx).. <i>Journal of Clinical Oncology</i> , 2013, 31, 529-529.	0.8	1
147	Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naïve metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 356-356.	0.8	3
148	Abstract B33: Osteopontin expression is an independent poor prognostic marker in gastric cancer radically resected. Preliminary report of translational study of ITACA-S (Intergroup Trial of Adjuvant Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
149	Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. <i>Neuro-Oncology</i> , 2012, 14, 1346-1356.	0.6	42
150	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	0.6	180
151	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	0.8	156
152	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012, 23, 1832-1837.	0.6	97
153	Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 3361-3367.	0.7	58
154	Leiomyosarcoma and sarcoma with myogenic differentiation. <i>Cancer</i> , 2012, 118, 5349-5357.	2.0	3
155	Anterior craniofacial resection for malignant paranasal tumors: A monoinstitutional experience of 366 cases. <i>Head and Neck</i> , 2012, 34, 78-87.	0.9	35
156	Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial. <i>Blood</i> , 2012, 120, 1984-1984.	0.6	1
157	Is <i>CTNNB1</i> mutational analysis predictive for progression in patients with sporadic desmoid tumors primarily observed?. <i>Journal of Clinical Oncology</i> , 2012, 30, 10016-10016.	0.8	0
158	Importance of early nutritional screening in patients with gastric cancer. <i>British Journal of Nutrition</i> , 2011, 106, 1773-1778.	1.2	59
159	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. <i>European Journal of Cancer</i> , 2011, 47, 724-731.	1.3	123
160	Natural History of Imatinib-naïve GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1646-1656.	2.1	116
161	Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. <i>British Journal of Cancer</i> , 2011, 104, 1256-1261.	2.9	66
162	Reply to Ilker Akyol, Hasan Soydan, and Ferhat Ates™ Letter to the Editor re: Nicola Nicolai, Rosalba Miceli, Andrea Necchi, et al. Retroperitoneal Lymph Node Dissection With No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>Eur Urol</i> 2010;58:912-8. <i>European Urology</i> , 2011, 59, e21-e22.	0.9	1

#	ARTICLE	IF	CITATIONS
163	Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up. <i>Annals of Surgical Oncology</i> , 2011, 18, 125-133.	0.7	141
164	Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 720-725.	0.7	199
165	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	1.3	471
166	Myeloablative doses of yttrium-90-antibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. <i>Cancer</i> , 2011, 117, 5074-5084.	2.0	23
167	Survival Prediction for Terminally Ill Cancer Patients: Revision of the Palliative Prognostic Score with Incorporation of Delirium. <i>Oncologist</i> , 2011, 16, 1793-1799.	1.9	93
168	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	0.6	42
169	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011, 22, 2495-2500.	0.6	31
170	Prognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers (OPCs).. <i>Journal of Clinical Oncology</i> , 2011, 29, 5573-5573.	0.8	1
171	Breast change perception in women after smoking cessation. A pilot study. <i>Tumori</i> , 2011, 97, 672-5.	0.6	0
172	The symptom interval in children and adolescents with soft tissue sarcomas. <i>Cancer</i> , 2010, 116, 177-183.	2.0	66
173	Pure Desmoplastic Melanoma. <i>Annals of Surgery</i> , 2010, 252, 1052-1057.	2.1	49
174	Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control. <i>Annals of Surgical Oncology</i> , 2010, 17, 1507-1514.	0.7	257
175	Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>European Urology</i> , 2010, 58, 912-918.	0.9	47
176	Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. <i>Cancer</i> , 2010, 116, 2429-2436.	2.0	93
177	Pretransplantation [ <sup>18</sup> F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. <i>Cancer</i> , 2010, 116, 5001-5011.	2.0	36
178	Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1322-1328.	0.8	58
179	Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 4589-4589.	0.8	4
180	Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size. <i>Journal of Clinical Oncology</i> , 2009, 27, 371-376.	0.8	55

#	ARTICLE	IF	CITATIONS
181	Distal clearance margin of 1 cm or less: a safe distance in lower rectum cancer surgery. <i>International Journal of Colorectal Disease</i> , 2009, 24, 317-322.	1.0	45
182	Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: A validation analysis. <i>Lung Cancer</i> , 2009, 66, 270-271.	0.9	7
183	Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences. <i>Biomarkers</i> , 2009, 14, 130-136.	0.9	29
184	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	5.1	1,920
185	Fluorodeoxyglucose Uptake Measured by Positron Emission Tomography and Standardized Uptake Value Predicts Long-Term Survival of CT Screening Detected Lung Cancer in Heavy Smokers. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1352-1356.	0.5	30
186	Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen. <i>Cancer</i> , 2008, 112, 481-488.	2.0	44
187	The prognostic impact of dedifferentiation in retroperitoneal liposarcoma. <i>Cancer</i> , 2008, 113, 1657-1665.	2.0	81
188	RISK OF DISTANT METASTASIS FOLLOWING RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND) ALONE IN CLINICAL STAGE I (CS I) NON-SEMINOMATOUS GERM CELL TESTICULAR TUMOURS (NSGCTTs). <i>Journal of Urology</i> , 2008, 179, 176-176.	0.2	0
189	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2008, 49, 2156-2162.	0.6	143
190	Lymph Node Metastases in Malignant Tumors of the Paranasal Sinuses. <i>JAMA Otolaryngology</i> , 2008, 134, 170.	1.5	139
191	Lung Cancer Stage is an Independent Risk Factor for Surgical Mortality. <i>Tumori</i> , 2008, 94, 362-369.	0.6	6
192	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 3303-3303.	0.6	26
193	Atrial fibrillation after non-cardiac surgery: P-wave characteristics and Holter monitoring in risk assessment†. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 31, 812-816.	0.6	20
194	Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease. <i>Neurology</i> , 2007, 68, 1141-1143.	1.5	141
195	Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. <i>European Journal of Cancer</i> , 2007, 43, 2691-2697.	1.3	43
196	Short-term effects of pamidronate on bone turnover: Can bone markers be considered predictive of the analgesic response?. <i>Oncology Reports</i> , 2007, 17, 1533-40.	1.2	6
197	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007, 21, 2316-2323.	3.3	142
198	Estimation of predictive accuracy in survival analysis using R and S-PLUS. <i>Computer Methods and Programs in Biomedicine</i> , 2007, 87, 132-137.	2.6	21

#	ARTICLE	IF	CITATIONS
199	Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure. <i>Annals of Surgical Oncology</i> , 2007, 14, 1583-1590.	0.7	70
200	Prognostic Value of Positron Emission Tomography (PET) Scan in Patients with Relapsed Hodgkin Lymphoma or Aggressive Non-Hodgkin Lymphoma Receiving Salvage Chemotherapy Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 3039-3039.	0.6	3
201	Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. <i>Cancer Research</i> , 2006, 66, 6219-6224.	0.4	43
202	Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2006, 13, 110-117.	0.7	141
203	Pathological features as predictors of recurrence after radical resection of gastric cancer. <i>British Journal of Surgery</i> , 2006, 93, 205-209.	0.1	45
204	Malignant peripheral nerve sheath tumors. <i>Cancer</i> , 2006, 107, 1065-1074.	2.0	358
205	Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1065-1071.	0.6	187
206	Extremity soft tissue sarcoma: The need for a differential surgical approach to primary tumor and local recurrence?. <i>Journal of Clinical Oncology</i> , 2006, 24, 9565-9565.	0.8	0
207	Which classification for ethmoid malignant tumors involving the anterior skull base?. <i>Head and Neck</i> , 2005, 27, 224-231.	0.9	19
208	Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. <i>Cancer</i> , 2005, 103, 402-408.	2.0	182
209	A Modified Prognostic Score for Patients with Curatively Resected Gastric Cancer. <i>Tumori</i> , 2005, 91, 221-226.	0.6	5
210	Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. <i>Annals of Oncology</i> , 2005, 16, 1449-1457.	0.6	92
211	Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate. <i>Journal of Clinical Oncology</i> , 2005, 23, 7669-7675.	0.8	196
212	Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2005, 23, 96-104.	0.8	248
213	A modified prognostic score for patients with curatively resected gastric cancer. <i>Tumori</i> , 2005, 91, 221-6.	0.6	5
214	Revising a Prognostic Index Developed for Classification Purposes: An Application to Gastric Cancer Data. <i>Journal of Applied Statistics</i> , 2004, 31, 817-830.	0.6	9
215	A Simple Model for Predicting Nodal Metastasis in Patients With Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors Undergoing Retroperitoneal Lymph Node Dissection Only. <i>Journal of Urology</i> , 2004, 171, 172-176.	0.2	69
216	Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. <i>Maturitas</i> , 2004, 47, 11-20.	1.0	58

#	ARTICLE	IF	CITATIONS
217	Evaluation of Reactive oxygen Metabolites in Frozen Serum Samples. Effect of Storage and Repeated Thawing. <i>International Journal of Biological Markers</i> , 2004, 19, 250-253.	0.7	23
218	Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation. <i>Annals of Surgery</i> , 2004, 240, 900-909.	2.1	452
219	Evaluation of reactive oxygen metabolites in frozen serum samples. Effect of storage and repeated thawing. <i>International Journal of Biological Markers</i> , 2004, 19, 250-253.	0.7	16
220	Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?. <i>Cancer</i> , 2003, 97, 1156-1163.	2.0	56
221	Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. <i>British Journal of Surgery</i> , 2003, 86, 84-87.	0.1	168
222	Lymphadenectomy in gastric cancer: prognostic role and therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2002, 28, 406-412.	0.5	53
223	c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients. <i>Breast</i> , 2002, 11, 286-294.	0.9	0
224	Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. <i>International Journal of Biological Markers</i> , 2002, 17, 253-258.	0.7	7
225	Perioperative Total Parenteral Nutrition in Malnourished, Gastrointestinal Cancer Patients: A Randomized, Clinical Trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2000, 24, 7-14.	1.3	226
226	The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 75, 65-73.	1.2	7
227	Early Gastric Cancer: Unrecognized Indicator of Multiple Malignancies. <i>World Journal of Surgery</i> , 2000, 24, 583-587.	0.8	10
228	Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 Serum Levels as Prognostic Indicators in Resected Non-Small Cell Lung Cancer. <i>International Journal of Biological Markers</i> , 1999, 14, 92-98.	0.7	9
229	Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1847-1856.	3.0	375
230	Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of "cures"™. <i>Breast Cancer Research and Treatment</i> , 1999, 53, 209-215.	1.1	39
231	Subtotal Versus Total Gastrectomy for Gastric Cancer. <i>Annals of Surgery</i> , 1999, 230, 170.	2.1	375
232	Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour?. <i>European Journal of Cancer</i> , 1998, 34, 825-830.	1.3	46
233	Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1349-1355.	3.3	20
234	The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 63, 261-267.	1.2	33



#	ARTICLE	IF	CITATIONS
235	Impact of Distal Clearance Margin on Oncologic Outcome after Restorative Resection of the Rectum. Tumori, 1997, 83, 907-911.	0.6	9
236	Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale, Design, Methodology, Organization, Data Management, Statistics and Accrual. Tumori, 1997, 83, 884-894.	0.6	32
237	Insular Carcinoma. American Journal of Surgical Pathology, 1997, 21, 1466-1473.	2.1	109
238	Total Versus Subtotal Gastrectomy. Annals of Surgery, 1997, 226, 613-620.	2.1	165
239	Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori, 1997, 83, 884-94.	0.6	14
240	Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Research and Treatment, 1996, 41, 177-185.	1.1	233
241	Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. Breast Cancer Research and Treatment, 1995, 34, 237-244.	1.1	18
242	Covid-19 outbreak in Lombardy: impact on reducing solid cancer diagnoses in 2020. International Journal of Cancer, 0, , .	2.3	5